Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.59 USD | +3.15% | +3.38% | +1.10% |
Apr. 01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
Mar. 27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.10% | 401M | |
-4.65% | 87.31B | |
+2.63% | 40.86B | |
-21.76% | 29.36B | |
+58.56% | 24.49B | |
-14.78% | 17.31B | |
-18.49% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon Concludes Enrollment in Phase 2 Trial of Geographic Atrophy Drug ANX007